Amgen Inc. plans to put its $41.7bn in cash as of the end of 2017 to work in 2018 in ways that may boost future earnings and "shareholder value," seeking acquisitions of drugs or companies that can help reverse the big biotech's flat to declining revenue trend.
There are not a lot of commercial-stage products for sale, so Amgen more than likely will purchase pipeline assets that could take years to bring to market – and years to significantly boost revenue. But investors hoping for near-term returns are in luck, because the company revealed in its fourth quarter earnings report on Feb. 1 that it has allocated $14
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?